Merck & Co Inc
MRK: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$596.00 | Fhx | Ydzdhbk |
Merck Earnings: Strong Overall Growth Led by Keytruda Supports Fair Value Increase
We are increasing Merck's fair value estimate to $120 from $114 based on strong first-quarter results that ran ahead of our expectations combined with a pipeline that is progressing well.